Khadijeh Abhari, Saeede Saadati, Zahra Yari, Hedayat Hosseini, Mehdi Hedayati, Shahabeddin Abhari, Seyyed Moayyed Alavian, Azita Hekmatdoost
Journal: Clinical nutrition ESPEN 2021;39():53-60
PMID: 32859329
BACKGROUND
The aim of this study was to evaluate the effects of supplementation with 10 spores of Bacillus coagulans (GBI-30) plus inulin in patients with non-alcoholic fatty liver disease (NAFLD).
METHODS
In a randomized, double-blind, placebo-controlled clinical trial, fifty three patients with NAFLD were randomly assigned to receive either a synbiotic or a placebo capsule for 12 weeks. The primary outcome was reduction in steatosis score in Fibroscan exam.
RESULTS
At the end of study, serum alanine aminotransferase and γ glutamine transaminase decreased significantly more in synbiotic group compared to placebo group (p = 0.001, and p = 0.004, respectively). Synbiotic supplementation significantly reduced serum tumor necrosis factor-α (p = 0.03) and nuclear factor-κB activity (p = 0.04). Moreover, hepatic steatosis reduced significantly more in synbiotic group compared to placebo group (p < 0.001).
CONCLUSION
Our results indicate that 12 weeks supplementation with B. coagulans plus inulin is beneficial for treatment of NAFLD and its related inflammation without any significant effects on related cardiovascular risk factors.
CLINICAL TRIALS
This trial was registered at irct.ir with number of IRCT20100524004010N23.
Copyright © 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.